Pembrolizumab plus chemotherapy for pleural mesothelioma

Article Oncology

Phase III Study of Pemetrexed in Combination With Cisplatin Versus Cisplatin Alone in Patients With Malignant Pleural Mesothelioma

Nicholas J. J. Vogelzang et al.

Summary: The purpose of this study was to evaluate the efficacy of pemetrexed plus cisplatin in the treatment of patients with malignant pleural mesothelioma. The results showed that compared to cisplatin alone, the combination of pemetrexed and cisplatin can prolong the overall survival time, progression-free survival time, and improve the response rates in patients with malignant pleural mesothelioma. Addition of folic acid and vitamin B-12 can significantly reduce the toxicity of the treatment.

JOURNAL OF CLINICAL ONCOLOGY (2023)

添加到收藏夹

Article Medicine, General & Internal

Pembrolizumab plus chemotherapy versus chemotherapy in untreated advanced pleural mesothelioma in Canada, Italy, and France: a phase 3, open-label, randomised controlled trial

Quincy Chu et al.

LANCET (2023)

添加到收藏夹

Article Oncology

Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

S. Popat et al.

ANNALS OF ONCOLOGY (2022)

添加到收藏夹

Review Public, Environmental & Occupational Health

Living with mesothelioma: A systematic review of patient and caregiver psychosocial support needs

Lauren J. Breen et al.

Summary: Research shows that mesothelioma patients and family caregivers desire better diagnosis delivery and access to palliative care. Patients seek emotional support, patient-centered treatment, and more information about disease progression and death, while caregivers require one-on-one practical and emotional support.

PATIENT EDUCATION AND COUNSELING (2022)

添加到收藏夹

Article Respiratory System

Malignant Pleural Mesothelioma Updates for Respiratory Physicians

Calvin Sidhu et al.

CLINICS IN CHEST MEDICINE (2021)

添加到收藏夹

Article Medicine, General & Internal

First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial

Paul Baas et al.

Summary: Nivolumab plus ipilimumab demonstrated significant improvement in overall survival compared to standard chemotherapy for unresectable malignant pleural mesothelioma. This first-in-class treatment regimen has been approved for previously untreated patients in the USA and showed promising outcomes with manageable adverse events.

LANCET (2021)

添加到收藏夹

Article Medicine, General & Internal

Assessment of Global Trends in the Diagnosis of Mesothelioma From 1990 to 2017

Zhen Zhai et al.

Summary: The incidence and mortality of mesothelioma are continuously increasing worldwide, especially in resource-limited regions with low sociodemographic index levels. Governments and medical institutions should consider formulating optimal policies and strategies for the targeted prevention and management of mesothelioma based on these findings.

JAMA NETWORK OPEN (2021)

添加到收藏夹

Article Medicine, General & Internal